Market capitalization | $112.60m |
Enterprise Value | $90.69m |
P/E (TTM) P/E ratio | 12.03 |
EV/FCF (TTM) EV/FCF | 43.39 |
EV/Sales (TTM) EV/Sales | 2.20 |
P/S ratio (TTM) P/S ratio | 2.73 |
P/B ratio (TTM) P/B ratio | 2.08 |
Revenue growth (TTM) Revenue growth | 65.60% |
Revenue (TTM) Revenue | $41.31m |
As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.
4 Analysts have issued a Sensus Healthcare, Inc. forecast:
4 Analysts have issued a Sensus Healthcare, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 41 41 |
66%
66%
|
|
Gross Profit | 25 25 |
72%
72%
|
|
EBITDA | 12 12 |
952%
952%
|
EBIT (Operating Income) EBIT | 12 12 |
768%
768%
|
Net Profit | 9.31 9.31 |
1,146%
1,146%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Sensus Healthcare, Inc. operates as a medical device company, which provides treatments for both oncological and non-oncological skin conditions. The firm's portfolio of treatment devices includes the SRT-100, SRT-100+ and SRT-100 Vision. Its main product, superficial radiation therapy (SRT), a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers and other skin conditions such as keloids. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.
Head office | United States |
CEO | Joseph Sardano |
Employees | 35 |
Founded | 2010 |
Website | www.sensushealthcare.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.